

Agile Therapeutics Investor Relations Department 101 Poor Farm Road Princeton, NJ 08540 United States

Visit IR website ☐ Sign-up for email alerts ☐

NASDAQ: AGRX	
Last Trade:	2.78
Trade Time:	4:00 PM ET Apr 26, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	1.93 - 5.60
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.

Our lead product candidate, Twirla® (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15. is a once-weekly prescription contraceptive patch. Twirla is based on our proprietary transdermal patch technology called Skinfusion® which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability.

Stock Performance



Press Releases [View all]

Mar 14, 2018

Abstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition

Mar 12, 2018

Agile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

Dec 22, 2017

Agile Therapeutics, Inc. Receives a

Complete Response Letter from the FDA for
Twirla® (AG200-15) for the Prevention of
Pregnancy

Nov 6, 2017

Agile Therapeutics Reports Third Quarter 2017 Financial Results

Oct 31, 2017

Agile Therapeutics Presents Additional Phase
3 SECURE Trial Results for Twirla® at the
American Society for Reproductive Medicine
(ASRM) Scientific Congress & Expo 2017

Financials [View all]

Mar 12, 2018 Annual Report (10-K)

Apr 25, 2018
Proxy Statement (DEF 14A)

Nov 6, 2017 Quarterly Report (10-Q)

Jul 28, 2017 Quarterly Report (10-Q)

May 8, 2017
Quarterly Report (10-Q)